Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone

Fineline Cube Feb 3, 2026
Company Deals

PrimeGenX Therapeutics Files Hong Kong IPO for Pumecitinib Platform

Fineline Cube Feb 3, 2026
Company Deals

Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis

Fineline Cube Feb 3, 2026
Company Deals

Arctic Vision-Mdco Technology Merger Builds Ophthalmology Platform

Fineline Cube Feb 3, 2026
Company Deals

SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal

Fineline Cube Feb 3, 2026
Policy / Regulatory

NMPA Releases 101st Batch of Generic Reference Drugs

Fineline Cube Feb 2, 2026
Company Drug

Venglustat Gaucher: Sanofi Meets Primary Endpoint in Phase 3 LEAP2MONO Study

Fineline Cube Feb 3, 2026
Company Drug

Eli Lilly Mounjaro Fails to Win EU Approval for HFpEF Heart Failure Indication

Fineline Cube Feb 3, 2026
Company Drug

Innovent Biologics’ IBI133 Receives Tacit Approval for Clinical Trial from China’s CDE

Fineline Cube Apr 17, 2024

The Center for Drug Evaluation (CDE) in China has granted tacit clinical trial approval to...

Company Drug

Shionogi’s Xofluza Gains Approval in Taiwan for Pediatric Influenza Treatment and Prophylaxis

Fineline Cube Apr 17, 2024

Shionogi & Co., Ltd, a leading Japanese pharmaceutical company, has announced that it has received...

Company Drug

Kangtai Biological Receives NMPA Approval for 20-Valent Pneumococcal Vaccine Clinical Trial

Fineline Cube Apr 17, 2024

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading biopharmaceutical company in China, has...

Company

Boehringer Ingelheim Surpasses Bayer in Pharma Sales with EUR 20.8 Billion in 2023

Fineline Cube Apr 17, 2024

Boehringer Ingelheim, a major German pharmaceutical company, has released its financial report for 2023, announcing...

Company Drug

KPC Pharmaceuticals Gets NMPA Green Light for Clinical Trial on Familial Mediterranean Fever Treatment

Fineline Cube Apr 17, 2024

Yunnan-based KPC Pharmaceuticals Inc., (SHA: 600422) has announced that it has received clinical trial approval...

Company Deals

AbbVie Partners with Medincell for Development of Long-Acting Injectable Therapies

Fineline Cube Apr 17, 2024

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, has entered into a partnership with France-based...

Company Drug

Carvykti CAR-T Therapy Sales Reach $157 Million in Q1 2024, Reports GenScript Subsidiary Legend Biotech

Fineline Cube Apr 17, 2024

GenScript Biotech Corporation (HKG: 1548), a leading Contract Research Organization (CRO) based in China, has...

Company

J&J’s Medical Technology Sector Rises 6.3% YOY Despite China’s VBP Impact

Fineline Cube Apr 17, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has reported its financial results for the first quarter...

Policy / Regulatory

China Unveils 2024 Plan to Combat Fraud in Medical Insurance Funds

Fineline Cube Apr 17, 2024

The National Healthcare Security Administration (NHSA) of China, in conjunction with the Supreme People’s Court,...

Policy / Regulatory

Chinese Authorities Launch Special Plan to Rectify Medical Insurance Fraud and Non-Compliance

Fineline Cube Apr 17, 2024

The National Healthcare Security Administration (NHSA) of China, in collaboration with the Supreme People’s Court,...

Drug Policy / Regulatory

China’s NMPA Releases 79th Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Apr 17, 2024

The National Medical Products Administration (NMPA) in China has released the 79th batch of reference...

Company Drug

AstraZeneca’s Imfinzi Shows Sustained Survival Benefit in Advanced Biliary Tract Cancer Trial

Fineline Cube Apr 17, 2024

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical and biopharmaceutical company, has this week announced 3-year...

Medical Device Policy / Regulatory

China’s NMPA Launches 2024 Medical Device Industry Standard Revision Plan

Fineline Cube Apr 17, 2024

The National Medical Products Administration (NMPA) has unveiled the “2024 Medical Device Industry Standard Revision...

Company Deals

Beijing Airdoc Leads RMB 500 Million Joint Venture to Invest in AI-Powered Healthcare

Fineline Cube Apr 17, 2024

Beijing Airdoc Technology Co., Ltd., a leading artificial intelligence (AI)-powered ophthalmology device company, has announced...

Company Drug

Sirnaomics Receives FDA Feedback on STP705 Development Plan for isSCC Treatment

Fineline Cube Apr 17, 2024

Sirnaomics Ltd (HKG: 2257), a leading biopharmaceutical company focused on the discovery and development of...

Company Drug

China Medical System’s Opzelura Approved in Macau for Vitiligo Treatment

Fineline Cube Apr 17, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that it has received market approval...

Company

Roche China’s Talent and Culture Vice President Chen Yanli Departs for New Opportunities

Fineline Cube Apr 16, 2024

Roche (SWX: ROG), the Swiss pharmaceutical giant, has announced the departure of Chen Yanli, who...

Company Drug

Easton Pharmaceutical Gets NMPA Nod for Generic Version of Merck KGaA’s Concor

Fineline Cube Apr 16, 2024

Easton Pharmaceutical Co., Ltd (SHA: 688513), based in Chengdu, has announced that it has received...

Company Drug

Sanofi Advances Phase I/II Trial of Trifunctional NK Cell Engager in Blood Cancers

Fineline Cube Apr 16, 2024

Sanofi (NASDAQ: SNY), a French multinational pharmaceutical company, has administered the first dose to a...

Company Drug

Roche’s Columvi Meets Overall Survival Endpoint in Diffuse Large B-Cell Lymphoma Trial

Fineline Cube Apr 16, 2024

Roche (SWX: RO), a leading Swiss pharmaceutical company, has announced that a late-stage clinical trial...

Posts pagination

1 … 326 327 328 … 618

Recent updates

  • Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone
  • PrimeGenX Therapeutics Files Hong Kong IPO for Pumecitinib Platform
  • Hengrui Resubmits Camrelizumab-Apatinib BLA for HCC to FDA
  • Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis
  • ZEISS ARTEVO Gets NMPA Approval for China Ophthalmology Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone

Company Deals

PrimeGenX Therapeutics Files Hong Kong IPO for Pumecitinib Platform

Company Medical Device

Hengrui Resubmits Camrelizumab-Apatinib BLA for HCC to FDA

Company Deals

Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.